Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Protara Therapeutics, Inc. (TARA)
Company Research
Source: GlobeNewswire
On track to report interim results from approximately 25 six-month evaluable BCG-Unresponsive patients in ADVANCED-2 trial in Q1 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in LMs; regulatory update expected in 1H 2026 Dosed first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support and expect to report interim results in 2H 2026 Recently completed approximately $86 million public offering extending cash runway into 2028 NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today highlighted recent updates and anticipated 2026 milestones. “On the heels of a remarkable year marked by meaningful progress across the entirety of our pipeline, we are entering 2026 with unwavering resolve to continue to execute on our mission to deliver transformativ
Show less
Read more
Impact Snapshot
Event Time:
TARA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARA alerts
High impacting Protara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TARA
News
- Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.MarketBeat
- Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]Yahoo! Finance
- Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral SupportGlobeNewswire
- Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.MarketBeat
TARA
Earnings
- 11/10/25 - Beat
TARA
Sec Filings
- 12/15/25 - Form 8-K
- 12/9/25 - Form 424B7
- 12/8/25 - Form 8-K
- TARA's page on the SEC website